How to promote the accessibility of technology in the era of hESC patents-A comparative analysis of the systems of the US and China.

Wei Zhang, Jiajv Chen, Wei Li, Hanyang Zhang

Abstract readReview

In one paragraph

Review in Stem cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wei ZhangSchool of Law, Zhejiang Gongshang University, Hangzhou 310018, China.

Jiajv ChenSchool of Law, Renmin University of China, Beijing 100872, China; Institute of Intellectual Property, University of Science and Technology of China, Hefei 230022, China.

Wei LiIntellectual Property Research Institute, Jinan University, Guangzhou 510632, China. Electronic address: iprecht@126.com.

Hanyang ZhangInstitute of Intellectual Property, University of Science and Technology of China, Hefei 230022, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have entered the era of human embryonic stem cell (hESC) patents and the focus of discussion has shifted to how to rebalance interests. A potential way is to limit hESC patents and seek more effective utilization forms, such as ethical limitation, compulsory licensing, antimonopoly law regulation, experimental exception, and open licensing. This paper compares the restrictive measures in two major hESC markets, the United States and China, and explores the possibility of a balanced interests system.

Indexed as

Human Embryonic Stem CellsChinaHumansTechnologyUnited States

Identifiers

PMID37738968

DOI10.1016/j.stemcr.2023.08.013

PMCPMC10656298

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.